Yip CY, Greystoke A, Abogunrin S, Belleli R, et al. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing >/=50% PD-L1: A United Kingdom health care perspective. Lung Cancer 2023;179:107171.
PMID: 36947997